AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Ixorine, a New Cyclopeptide Alkaloid from the Branches of Ixora brevifolia

 Uncategorized  Comments Off on Ixorine, a New Cyclopeptide Alkaloid from the Branches of Ixora brevifolia
May 102016
 

Figure 2 Selected key HMBC (1H 13C) and NOESY (1H 1H) correlations for ixorine (1). 

STR1

Figure 1 Structures of compounds 14 isolated from the branches of I. brevifolia

Ixorine (1)

HRESIMS m/z, calcd.: C30H40N4O4 [M + H]+: 521.3044; found: 521.3049; [α]D20 = -292.3 (c 0.001, CHCl3); 1H NMR (300 MHz, CDCl3) and 13C NMR (75 MHz, CDCl3), see Table 1.

Table 1 NMR spectroscopic data (300 MHz, CDCl3) for ixorine (1

Position δC δH (mult., J in Hz) HMBC COSY
1 156.3 H-14, H-16
2
3 81.7 4.91 (dd, 8.0, 2.1) H-4, H-18, H-19 H-4
4 55.6 4.44 (dd, 9.0, 8.0) H-20 (NH)
5 171.6 H-6 (NH)
6 5.94 (d, 6.3, NH)
7 55.2 4.30 (m) H-28 H-28
8 167.2 H-28
9 6.20 (sl, NH)
10 125.7 6.56 (m)
11 118.4 6.40 (d, 6.6) H-13
12 131.8 H-14
13 131.7 7.03 (m) H-14
14 121.9 7.15 (m)
15 122.7 7.03 (m) H-16
16 130.2 6.92 (m)
17 29.3 2.00 (m) H-18, H-19 H-18, H-19
18 20.4 1.25 (d, 7.2) H-17, H-19
19 15.2 1.00 (d, 6.6) H-17
20 6.94 (m, NH)
21 172.4 H-22, H-23
22 75.2 2.40 (d, 4.2) H-24, H-25, H-26, H-27 H-26, H-27
23 27.8 2.05 (m) H-24, H-25 H-24, H-25
24 21.0 1.05 (d, 6.9)
25 17.6 0.93 (d, 6.6)
26 43.1 2.14 (s) H-27
27 43.1 2.14 (s)
28 37.1 2.76 (dd, 13.8, 4.5)/3.07 (m) H-30, H-30’ H-28
29 135.7 H-7, H-28, H-31, H-31’
30, 30’ 129.6 7.15 (m) H-31, H-31’
31, 31’ 129.0 7.34 (m)
32 127.4 7.24 (m) H-30, H-30’

 

Journal of the Brazilian Chemical Society

On-line version ISSN 1678-4790

J. Braz. Chem. Soc. vol.27 no.4 São Paulo Apr. 2016

http://dx.doi.org/10.5935/0103-5053.20150326

ARTICLES

Ixorine, a New Cyclopeptide Alkaloid from the Branches of Ixora brevifolia

Rebeca P. Medinaa  , Ivânia T. A. Schuquela  , Armando M. Pominia  , Cleuza C. Silvaa  , Cecília M. A. Oliveirab  , Lucília Katob  , Celso V. Nakamurac  , Silvana M. O. Santin*  a 

aDepartamento de Química, Universidade Estadual de Maringá, Av. Colombo 5790, 87020-900 Maringá-PR, Brazil

bInstituto de Química, Universidade Federal de Goiás, Campus II, Samambaia, 74001-970 Goiânia-GO, Brazil

cDepartamento de Análises Clínicas e Biomedicina, Universidade Estadual de Maringá, Av. Colombo 5790, 87020-900 Maringá-PR, Brazil

ABSTRACT

The isolation and structure determination of new cyclic peptide alkaloid ixorine, along with five known constituents frangulanine, syringaresinol, cinnamtannin B-1, daucosterol and mannitol from the branches of Ixora brevifolia are described. The cyclic peptide frangulanine is being described for the first time in the Rubiaceae family. The structures were elucidated on their spectral data basis, mainly one- (1H, 13C, DEPT) and two-dimensional (COSY, NOESY, HSQC and HMBC) nuclear magnetic resonance (NMR) and by comparison with data from the literature. The mixture of two cyclopeptide alkaloids showed weak activity against Leishmania amazonensis……..http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-50532016000400753&lng=en&nrm=iso&tlng=en

Key words: Ixora brevifolia,  Rubiaceae,  cyclopeptide alkaloids,  Leishmania

see……….http://www.scielo.br/pdf/jbchs/v27n4/0103-5053-jbchs-27-04-0753-suppl01.pdf

SUPPLEMENTARY INFORMATION

1D and 2D NMR spectra for compounds 12 are available free of charge online

0103-5053-jbchs-27-04-0753-suppl01.pdf

*e-mail: smoliveira@uem.br

////

Share

Arbaclofen

 Uncategorized  Comments Off on Arbaclofen
May 102016
 

Arbaclofen placarbil.svg

Arbaclofen placarbil

(3R)-3-(4-chlorophenyl)-4-[[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino]butanoic acid

NDA filed

A GABA (B) receptor agonist potentially for the treatment of muscle spasticity.

AGI-006; STX-209; OS-440

CAS No. 69308-37-8 free

847353-30-4 placarbil

Arbaclofen placarbil (ar-bac-loe-fen pla-kar-bil, also known as XP19986) is a prodrug of Rbaclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.[1]

Arbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties. ArbaclofenPlacerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned by XenoPort in 2011 for the treatment of GERD. On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.

Autism spectrum disorder (ASD) is a behaviorally defined disorder which has increased in prevalence over the last two decades. Despite decades of research, no effective treatment is currently available. Animal models, as well as other lines of evidence, point to abnormalities in the balance of cortical excitation to inhibition in individuals with ASD, with this imbalance resulting in an overall increase in cortical excitation. To reduce cortical excitatory glutamate pathways, arbaclofen, a selective agonist of the gamma aminobutyric acid receptor type B, has been developed. This article reviews the evidence for this treatment for ASD using a systematic review methodology. Overall, a systematic search of the literature revealed 148 relevant references with the majority of these being review papers or news items that mentioned the potential promise of arbaclofen. Five original studies were identified, four of which used STX209, a form of arbaclofen developed by Seaside Therapeutics, Inc., and one which used R-baclofen. In an animal model, treatment of Fragile X, a genetic disease with ASD features, demonstrated a reversal of behavioral, neurological, and neuropathological features associated with the disease. One double-blind, placebo-controlled study treated children and adults with Fragile X. Results from this study were promising, with signs of improvement in social function, especially in the most severely socially impaired. Two studies, one open-label and one double-blind, placebo-controlled, were conducted in children, adolescents, and young adults with ASD. These studies suggested some improvements in socialization, although the effects were limited and may have been driven by individuals with ASD that were higher-functioning. These studies and others that have used arbaclofen for the treatment of gastroesophageal reflux suggest that arbaclofen is safe and well-tolerated. Clearly, further clinical studies are needed in order to refine the symptoms and characteristics of children with ASD that are best treated with arbaclofen.

 

Arbaclofen placarbil.png

 

 Fig. 1.

Fig. 1.

The Structures of R-baclofen (1), arbaclofen placarbil (2), R-baclofen lactam (3), and the potential γ-hydroxy metabolite of R-baclofen (4).


1. Chem. Pharm. Bull. 1995, 43, 1302-1306.



1. J. Am. Chem. Soc. 2005, 127, 119-125.

2. WO2007066828A1 / US2009137819A1.


1. US2012029230A1

 


1. Tetrahedron-Asymmetr. 1992, 3, 1213-1221.

2. Tetrahedron Lett. 1991, 32, 6949-6952.

.

References

Arbaclofen placarbil
Arbaclofen placarbil.svg
Systematic (IUPAC) name
(3R)-3-(4-chlorophenyl)-4-[[[(1S)-2-methyl-1-[(2-methylpropanoyl)oxy]propoxy]carbonyl]amino]butanoic acid
Clinical data
Pregnancy
category
  • N/A
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number 847353-30-4
ATC code none
PubChem CID 11281011
ChemSpider 9456008
KEGG D08861 Yes
ChEMBL CHEMBL2107312 Yes
Chemical data
Formula C19H26ClNO6
Molar mass 399.86 g/mol

///////AGI-006,  STX-209,  OS-440, Arbaclofen, autism spectrum disorder, Fragile X, gamma-aminobutyric acid, arbaclofen, R-baclofen, STX209

CC(C)[C@@H](OC(=O)C(C)C)OC(=O)NC[C@H](CC(=O)O)C1=CC=C(C=C1)Cl

DISCLAIMER

I , Dr A.M.Crasto is writing this blog to share the knowledge/views, after reading Scientific Journals/Articles/News Articles/Wikipedia. My views/comments are based on the results /conclusions by the authors(researchers). I do mention either the link or reference of the article(s) in my blog and hope those interested can read for details. I am briefly summarising the remarks or conclusions of the authors (researchers). If one believe that their intellectual property right /copyright is infringed by any content on this blog, please contact or leave message at below email address amcrasto@gmail.com. It will be removed ASAP
Share
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: